Allergan PLC. (AGN) Holdings Lifted by RiverPark Advisors LLC

RiverPark Advisors LLC grew its stake in shares of Allergan PLC. (NYSE:AGN) by 6.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,200 shares of the company’s stock after buying an additional 400 shares during the period. RiverPark Advisors LLC’s holdings in Allergan PLC. were worth $1,507,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. GWM Advisors LLC raised its position in shares of Allergan PLC. by 0.4% during the first quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock worth $300,000 after purchasing an additional 5 shares during the period. Burns J W & Co. Inc. NY raised its position in shares of Allergan PLC. by 0.7% during the second quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock worth $220,000 after purchasing an additional 6 shares during the period. Gilder Gagnon Howe & Co. LLC raised its position in shares of Allergan PLC. by 0.5% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock worth $405,000 after purchasing an additional 9 shares during the period. Trust Co raised its position in shares of Allergan PLC. by 0.8% during the first quarter. Trust Co now owns 1,224 shares of the company’s stock worth $292,000 after purchasing an additional 10 shares during the period. Finally, Berkeley Capital Partners LLC raised its position in shares of Allergan PLC. by 0.3% during the second quarter. Berkeley Capital Partners LLC now owns 3,721 shares of the company’s stock worth $905,000 after purchasing an additional 10 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Allergan PLC. (AGN) Holdings Lifted by RiverPark Advisors LLC” was originally published by BBNS and is owned by of BBNS. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://baseballnewssource.com/markets/riverpark-advisors-llc-has-1-51-million-position-in-allergan-plc-agn/1599740.html.

Allergan PLC. (AGN) opened at 223.58 on Friday. The firm has a market cap of $74.74 billion, a PE ratio of 6.81 and a beta of 1.18. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80. The firm has a 50-day moving average price of $232.72 and a 200-day moving average price of $236.77.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. During the same period in the prior year, the company posted $3.35 EPS. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, equities analysts expect that Allergan PLC. will post $16.25 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.25%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.

A number of equities research analysts recently issued reports on the company. Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price on the stock in a research report on Monday, June 26th. Wells Fargo & Company reissued an “outperform” rating and issued a $280.00 target price (up previously from $270.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. UBS AG reissued an “outperform” rating and issued a $275.00 target price on shares of Allergan PLC. in a research report on Wednesday, August 9th. Royal Bank Of Canada set a $284.00 price target on Allergan PLC. and gave the company a “buy” rating in a research note on Sunday, July 16th. Finally, Deutsche Bank AG restated a “buy” rating and issued a $273.00 price target (up from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company’s stock. Allergan PLC. presently has a consensus rating of “Buy” and a consensus price target of $274.69.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with our FREE daily email newsletter.

 


Latest News

Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Cleveland Indians Winning Streak Reaches 18
Cleveland Indians Winning Streak Reaches 18


Leave a Reply

 
© 2006-2017 BBNS.